Morepen Laboratories reported strong Q4 FY26 performance with net profit rising 69% YoY to Rs 20 crore and gross revenue increasing 22% YoY to Rs 472 crore. Revenue growth during the quarter was supported by export momentum and expansion in the medical devices business, while operational momentum strengthened toward the latter part of FY26.
The API business grew 17% in Q4 FY26 while the medical devices business grew 31%. FY26 standalone gross revenue crossed Rs 1,700 crore up 8%. The board proposed 10% dividend for FY26.
Backed by its multi-year Rs 825 crore (US$ 91 million) global CDMO mandate received in February 2026 from a leading global multinational, Q4 FY26 marked the commencement of commercial production under Morepen’s long-duration manufacturing partnership program. The Company has completed validation batches and aligned initial supply schedules for phased delivery under the program, with supplies expected to commence shortly.
The quarter also witnessed continued investments toward manufacturing scale-up, regulated-market programs and medical devices expansion. EBITDA stood at Rs. 32 crore in Q4 FY26 compared to Rs 33 crore in Q4 FY25, reflecting these growth investments. The company believes these initiatives are intended to support operating leverage, margin expansion and long-term growth visibility over the coming quarters.
Commenting on the company’s strategic direction, Sushil Suri, chairman and managing director, Morepen Laboratories, said, “Over the years, Morepen has built strong manufacturing capabilities, regulatory credibility and global customer relationships. We are now entering the next phase of growth focused on long-duration manufacturing partnerships, scale expansion and improved operating leverage.”
Suri added, “The company’s business is progressively evolving from a traditional API model toward a manufacturing-led platform driven by long-duration customer programs, recurring revenues, process scale-up and regulated-market partnerships.”
Sanjay Suri, executive director and CEO – API, commenting on the manufacturing expansion and product pipeline, said,“We are expanding manufacturing capacity from ~500 KL toward ~800 KL, with a longer-term roadmap toward ~1000 KL. Increasing scale, improved product mix and long-duration supply programs are expected to support stronger margins and earnings visibility over the medium term.”
He added, “The company has also completed a pivotal bioequivalence study for Resmetirom 100 mg, an oral thyroid hormone receptor-beta agonist used in the treatment of moderate to advanced liver fibrosis associated with MASH. The study covers major regulated markets outside the US and represents an important step in strengthening Morepen’s globally relevant specialty pipeline.”
Alongside the Pharma transition, Morepen’s Medical Devices business continued to scale strongly, with FY26 revenue growing 21% to Rs. 598 crore and an installed base of nearly 17 million repeat users. The Medical Devices platform is being developed as a separate high-growth healthcare business focused on chronic care, consumer diagnostics, CGM opportunities and connected healthcare integration.
Strategic investments across manufacturing scale-up, Devices expansion, customer acquisition and healthcare platforms impacted near-term profitability during FY26. The Company believes these investments position the business for improved operating leverage, margin expansion and stronger long-term earnings visibility.
